Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

BioLineRX Ltd (BLRX)

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/25/2011

Market Cap

62,045,384

Shares Outstanding

1,086,590,000

Weighted SO

72,439,278

Total Employees

N/A

Upcoming Earnings

09/04/2024

Similar Tickers

ARDX --.--%

LXRX --.--%

MCRB --.--%

IBRX --.--%

XFOR --.--%

MREO --.--%

INZY --.--%

TERN --.--%

LPTX --.--%

Beta

0.8710

Last Div

0.0000

Range

0.51-2.53

Chg

0.0418

Avg Vol

348917

Mkt Cap

62045384

Exch

NASDAQ

Country

IL

Phone

972 8 642 9100

DCF Diff

0.3100

DCF

0.4100

Div Yield

0.0000

P/S

5.3235

EV Multiple

-1.6040

P/FV

3.9941

Div Yield %

0.0000

P/E

-1.0614

PEG

0.0069

Payout

0.0000

Current Ratio

1.1376

Quick Ratio

1.0455

Cash Ratio

0.1909

DSO

104.5676

DIO

189.4511

Op Cycle

294.0187

DPO

541.4014

CCC

-247.3827

Gross Margin

0.5224

Op Margin

-3.3425

Pretax Margin

-4.2169

Net Margin

-4.2169

Eff Tax Rate

0.0533

ROA

-0.9525

ROE

-3.2510

ROCE

-1.9260

NI/EBT

1.0000

EBT/EBIT

1.2616

EBIT/Rev

-3.3425

Debt Ratio

0.2193

D/E

0.8663

LT Debt/Cap

0.3543

Total Debt/Cap

0.4642

Int Coverage

-18.1533

CF/Debt

-2.5368

Equity Multi

3.9510

Rec Turnover

3.4906

Pay Turnover

0.6742

Inv Turnover

1.9266

FA Turnover

6.7801

Asset Turnover

0.2259

OCF/Share

-0.3962

FCF/Share

-0.3990

Cash/Share

0.3889

OCF/Sales

-2.4625

FCF/OCF

1.0070

CF Coverage

-2.5368

ST Coverage

-6.9209

CapEx Coverage

-143.5050

Div&CapEx Cov

-143.5050

P/BV

3.9941

P/B

3.9941

P/S

5.3235

P/E

-1.0614

P/FCF

-2.1468

P/OCF

-1.8175

P/CF

-1.8175

PEG

0.0069

P/S

5.3235

EV Multiple

-1.6040

P/FV

3.9941

DPS

0.0000

Latest Headlines (EST)

No Headlines Found

Revenue Product Segmentation